Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients

por Escobedo-Aedo, P., Merayo-Cano, J., Mata Iturralde, L., Muñoz Lorenzo, L., Ovejero, S., Sánchez Alonso, S.
Publicado 2022

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)

por Escobedo-Aedo, P. J., Merayo-Cano, J., Sánchez Alonso, S., Ovejero, S., Muñoz Lorenzo, L., Mata Iturralde, L.
Publicado 2023

Pending challenges to e-mental health in the COVID-19 era: Acceptability of a smartphone-based ecological momentary assessment application among patients with schizophrenia spectru...

por Lopez-Morinigo, J.-D., Luisa, B.-E. Maria, Porras-Segovia, A., Martínez, A. Sánchez-Escribano, Escobedo-Aedo, P.-J., Ruiz-Ruano, V. González, Mata-Iturralde, L., Muñoz-Lorenzo, L., Sánchez-Alonso, S., Artés-Rodríguez, A., Baca-Garcia, E.
Publicado 2021